Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Novartis AG (NVS)

89.2454   -0.235 (-0.26%) 08-20 14:45
Open: 90.17 Pre. Close: 89.48
High: 89.8 Low: 89.115
Volume: 1,327,209 Market Cap: 205103M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 90.254 - 90.601 90.601 - 91
Low: 87.165 - 87.538 87.538 - 87.966
Close: 88.782 - 89.384 89.384 - 90.077

Technical analysis

as of: 2019-08-20 2:30:39 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 107.27     One year: 110.96
Support: Support1: 86.74    Support2: 72.17
Resistance: Resistance1: 91.84    Resistance2: 95.00
Pivot: 90.26
Moving Average: MA(5): 89.15     MA(20): 90.81
MA(100): 86.97     MA(250): 81.80
MACD: MACD(12,26): -0.47     Signal(9): -0.21
Stochastic oscillator: %K(14,3): 45.38     %D(3): 40.93
RSI: RSI(14): 44.11
52-week: High: 95.00  Low: 72.73  Change(%): 18.8
Average Vol(K): 3-Month: 202672  10-Days: 192847

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
NVS has closed above bottom band by 30.1%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 19 Aug 2019 20:08:39 Z
5 Companies Still Run by Families

Mon, 19 Aug 2019 14:15:07 Z
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

Mon, 19 Aug 2019 11:09:09 Z
5 Biggest New Drug Approvals Potentially on the Way in 2019

Fri, 16 Aug 2019 19:08:53 Z
A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

Fri, 16 Aug 2019 17:14:36 Z
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare
Industry:  Drug Manufacturers - Major
Shares Out. (M) 2290.00
Shares Float (M) 2150.00
% Held by Insiders
% Held by Institutions 11.69
Shares Short (K) 3780
Shares Short P. Month (K)

Stock Financials

EPS 4.870
EPS Est. Current Year 4.750
EPS Est. Next Year 5.250
EPS Est. Next Quarter 1.280
Forward EPS 5.631
Book Value (p.s.) 22.440
PEG Ratio 2.17
Profit Margin 21.15
Operating Margin 21.78
Return on Assets (ttm) 5.7
Return on Equity (ttm) 10.7
Qtrly Rev. Growth 3.2
Gross Profit (p.s.) 15.755
Sales Per Share
EBITDA (p.s.) 7.380
Qtrly Earnings Growth -12.50
Operating Cash Flow (M) 13340.00
Levered Free Cash Flow (M) 15190.00

Stock Valuations

P/E 18.32
P/E Growth Ratio
P/BV 3.98
P/S 8776366080.00
P/CF 15.32

Dividends & Splits

Dividend 2.890
Dividend Yield 0.03
Dividend Pay Date 2019-03-13
Ex-Dividend Date 2019-03-04
Forward Dividend 2.830
Last Split Date 2019-04-09
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.